Filter your results
- 1
- 1
- 2
- 2
- 1
- 1
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq CohortActa Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩
Journal articles
hal-03660920v1
|
||
|
Early major adverse cardiovascular events following the initiation of the anti-interleukin 12/23 antibody ustekinumab. A population-based case-time-control studyJournal of Investigative Dermatology, 2019, 139 (9), pp.S230-S230. ⟨10.1016/j.jid.2019.07.097⟩
Journal articles
hal-02303760v1
|